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Akkermansia muciniphila-derived extracellular vesicles
inﬂuence gut permeability through the regulation of
tight junctions
Chaithanya Chelakkot1,8, Youngwoo Choi2,8, Dae-Kyum Kim1, Hyun T Park2, Jaewang Ghim3,
Yonghoon Kwon2, Jinseong Jeon2, Min-Seon Kim4, Young-Koo Jee5, Yong S Gho2, Hae-Sim Park6,
Yoon-Keun Kim7 and Sung H Ryu1,2
The gut microbiota has an important role in the gut barrier, inﬂammation and metabolic functions. Studies have identiﬁed a
close association between the intestinal barrier and metabolic diseases, including obesity and type 2 diabetes (T2D). Recently,
Akkermansia muciniphila has been reported as a beneﬁcial bacterium that reduces gut barrier disruption and insulin resistance.
Here we evaluated the role of A. muciniphila-derived extracellular vesicles (AmEVs) in the regulation of gut permeability. We
found that there are more AmEVs in the fecal samples of healthy controls compared with those of patients with T2D. In
addition, AmEV administration enhanced tight junction function, reduced body weight gain and improved glucose tolerance in
high-fat diet (HFD)-induced diabetic mice. To test the direct effect of AmEVs on human epithelial cells, cultured Caco-2 cells
were treated with these vesicles. AmEVs decreased the gut permeability of lipopolysaccharide-treated Caco-2 cells, whereas
Escherichia coli-derived EVs had no signiﬁcant effect. Interestingly, the expression of occludin was increased by AmEV
treatment. Overall, these results imply that AmEVs may act as a functional moiety for controlling gut permeability and that the
regulation of intestinal barrier integrity can improve metabolic functions in HFD-fed mice.
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INTRODUCTION
The digestive tract is home to trillions of microbes, termed the
gut microbiota, which affect energy homeostasis,1
endotoxemia,2 metabolism and the immune response3 during
various diseases; additionally, the gut microbiota establishes a
symbiotic relationship with the host in healthy mice and
humans. Recently, metagenomic studies have found that
microbial communities differ between normal and obese
subjects.4,5 The bacterium Akkermansia muciniphila may repre-
sent 3–5% of the microbial composition in the healthy human
intestinal tract6,7 and have a crucial role in the regulation of the
gut barrier and other homeostatic and metabolic functions.8
Studies have identiﬁed a loss in abundance of A. muciniphila in
patients with obesity and type 2 diabetes (T2D).9,10 However,
the precise physiological mechanisms affected by this bacterium
during metabolic disorders and intestinal permeability regula-
tion remain unclear.
The intestinal barrier is the major barrier that separates our
body from the external environment and is essential for the
maintenance of intestinal homeostasis and metabolism.11
Alterations in intestinal barrier integrity are closely associated
with the onset of metabolic diseases. Obese individuals
manifest metabolic endotoxemia as a result of increased
intestinal permeability, and this is thought to be a crucial
factor responsible for chronic inﬂammation.12,13 The gut
microbiota has a critical role in contributing to intestinal
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permeability and metabolic endotoxemia-induced inﬂamma-
tion in patients with obesity and diabetes.14
Extracellular vesicles (EVs) are lipid bilayer structures
secreted from the gut microbiota, including from both
Gram-negative and -positive bacteria.15,16 A variety of bacteria
constitutively produce EVs, deﬁned as spherical lipid bilayers
with an average diameter of 20–200 nm.17 EVs are composed
of proteins, lipids, nucleic acids, lipopolysaccharides and other
virulence factors associated with pathogenesis.18–20 Recent
evidence suggests that EVs released by bacteria have diverse
roles in the microbial community by transferring genetic
material and proteins from the bacteria to the host.21 EVs
can also directly interact with immune cells and epithelial cells
to initiate several signaling pathways and can be considered as
functional units of the gut microbiota that mediate host–
pathogen interactions. In addition, our previous study observed
that EVs affected glucose metabolism by inducing insulin
resistance. EVs affected the insulin signaling pathway, resulting
in the inhibition of Akt phosphorylation.22 However, the
unique mechanisms by which EVs regulate intestinal perme-
ability and glucose homeostasis are not fully understood.
In this study, we evaluated the mechanism underlying the
inﬂuence of A. muciniphila-derived EVs (AmEVs) on gut
barrier function. AmEV treatment increased tight junction
protein expression in Caco-2 cells and ultimately improved
intestinal barrier integrity in high-fat diet (HFD)-induced
diabetic mice in an AMPK-dependent manner. These results
suggest that EVs are an important moiety in the regulation of
gut permeability and metabolic functions by A. muciniphila.
MATERIALS AND METHODS
Materials
A. muciniphila bacteria (ATCC BA-835) were purchased from the
American Type Culture Collection (Manassas, VA, USA). The AMPK
inhibitor, compound C (171260), was purchased from Merck (Boston,
MA, USA).
Ethics statement
This study was carried out in strict accordance with the recommenda-
tions in the Guide for the Care and Use of Laboratory Animals of the
National Institute of Health (Bethesda, MD, USA). The experimental
protocols were approved by the Institutional Animal Care and Use
Committee at POSTECH, Pohang, Republic of Korea (permit
number: POSTECH-2015-0018). All animal experiments were
planned to minimize suffering.
Bacterial culture and EV isolation
A. muciniphila (ATCC BAA-835) was cultured under anaerobic
conditions (99% N2 at 37 °C) until the optical density at 600 nm
reached 1.5 as previously described.7 The isolation of EVs was
performed as previously described.23 Brieﬂy, bacterial cultures were
pelleted at 10 000 g for 20 min, and the supernatant was ﬁltered
through a 0.45-μm vacuum ﬁlter. The ﬁltrate was enriched using
QuixStand (GE Healthcare, Little Chalfont, UK) and subsequently
ﬁltered through a 0.22- μm bottle-top ﬁlter (Sigma-Aldrich, St Louis,
MO, USA). The ﬁltrate was pelleted by ultracentrifugation in a 45 Ti
rotor (Beckman Coulter, Fullerton, CA, USA) at 150 000 g for 2 h at
4 °C. The ﬁnal pellets were resuspended in phosphate-buffered saline
(PBS) and stored at − 80 °C. The EVs were analyzed by transmission
electron microscopy, dynamic light scattering and sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) followed by gel
staining with Coomassie Brilliant Blue R-250.
Mammalian cell culture
Caco-2 cells were cultured in Dulbecco’s modiﬁed Eagles medium
supplemented with 10% fetal bovine serum, 4 mM glutamine, 1%
nonessential amino acids, 4.5 g l− 1 D-glucose, 110 mg l− 1 sodium
pyruvate and 1% antibiotic cocktail.24,25 For cell signaling experi-
ments, Caco-2 cells were treated with 5 μg ml− 1 lipopolysaccharide
(LPS) with or without 1 μg ml− 1 EV, and the cells were lysed after 4 h
for cell signaling experiments. For dose-dependency studies, Caco-2
cells were treated with 0.1, 1 and 10 μg ml− 1 EVs, and the cells were
lysed after 4 h. For time-dependent studies, Caco-2 cells were treated
with 1 μg ml− 1 EV, and the cells were lysed at 0, 2, 4 and 8 h. Cell
lysates were used to examine the protein expression by western
blotting.
In vitro permeability assay
In vitro permeability was determined by measuring the ﬂow of
ﬂuorescein isothiocyanate (FITC)-dextran across the apico-
basolateral layer in a Caco-2 monolayer cell culture as previously
described.26 Caco-2 cells were cultured on collagen-coated transwell
chambers as mentioned above for approximately 3 weeks, and the
media was replaced every 2 days to generate monolayers. Monolayer
formation was conﬁrmed by measuring the trans-epithelial electrical
resistance27,28 using a Millicell ERS-2 epithelial cell volt-ohm meter
(Merck Millipore, MA, USA). Once the trans-epithelial resistance
reached a plateau, the cells were considered to be differentiated and
organized in a tight monolayer. Caco-2 monolayers were treated with
LPS, LPS+Escherichia coli EV or LPS+AmEVs. Untreated cells were
used as controls. After 4 h, the trans-epithelial electrical resistance was
measured again to analyze the LPS- or EV-induced changes in
intestinal permeability. The apical chamber was then washed with
Hank’s Balanced Salt Solution, and 1 mg ml− 1 FITC-dextran was
added to the apical chamber (0-h time point). After 6 h, 100 μl of
media was collected from the basal chamber, and ﬂuorescence
intensity at an excitation of 490 nm and an emission of 530 nm was
measured in each sample using a spectroﬂuorometer (Varian Cary
Eclipse, CA, USA). The concentration of FITC-dextran in the sample
was calculated using a standard curve of FITC-dextran.
Animal studies
Animal experiments were performed using C57BL/6 mice (6–8-week-
old males) maintained under a 12 h light/dark cycle with free access to
food and water. Mice were fed a 60% HFD for 12 weeks. After
inducing a diabetic phenotype in the mice, EVs were orally adminis-
tered for 2 weeks. Animal body weight was measured at the indicated
time points. For the glucose tolerance test, mice were subjected to
fasting for 16 h, followed by intraperitoneal injection with glucose at a
dose of 1 g kg− 1 body weight (G7021, Sigma-Aldrich). Blood glucose
concentrations were measured at the indicated time points using a
glucometer (Accu-Check Performa; Roche, Basal, Switzerland), and
blood was collected from the tail vein. Animals were then killed, and
the colons were removed for morphological analysis.
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In vivo permeability assay
In vivo intestinal permeability was measured using the FITC-dextran
assay as previously described.26,29–31 Mice were fed with the HFD for
12 weeks, followed by an oral gavage of 10 μg per mice AmEVs for a
period of 2 weeks every other day. The animals were starved for 6 h
prior to the start of the experiments. FITC-dextran (Sigma Aldrich
#46944) was orally gavaged at a dosage of 400 mg kg− 1. Blood samples
were obtained by retro-orbital bleeding, and the ﬂuorescence intensity
in the serum was measured at an excitation wavelength of 490 nm and
an emission wavelength of 530 nm using a spectroﬂuorometer (Cary
Eclipse Fluorescence Spectrophotometer; Varian, Palo Alto, CA, USA).
FITC-dextran diluted in PBS was used to plot a standard curve, and
the serum concentration of FITC-dextran was calculated. The experi-
ment was conducted a minimum of three times, with a sample size of
at least six mice per group.
Immunohistochemistry
Paraformaldehyde-ﬁxed, parafﬁn-embedded tissue sections were
stained using a Vectastain Kit (#PK-6161; Vector Laboratories, Inc.,
Burlingame, CA, USA). After the removal of parafﬁn and dehydration,
the tissue sections were washed in PBS, and the endogenous
peroxidase activity was quenched using 0.3% H2O2. Sections were
blocked with 5% horse serum diluted in PBST (0.02% Tween 20 in
PBS) and incubated with primary antibodies against occludin
(ab31721, Abcam, Cambridge, UK), claudin-5 (ab15106, Abcam) or
zonal occludens-1 (ab59720, Abcam) overnight at 4 °C. The sections
were then washed in PBST and incubated with the biotinylated
secondary antibody for 2 h at 25 °C. A ﬂuorescently labeled secondary
antibody (Invitrogen, Carlsbad, CA, USA) was used for ﬂuorescence
staining. Nuclei were stained with 4′,6-diaminido-2-phenylindole and
visualized under a Leica DM750 light microscope (Leica Microsys-
tems, Wetzlar, Germany).
Immunoblotting
To observe the cell signaling pathway, HFD and EV-treated colon
tissue samples and EV-treated, serum-fasted Caco-2 cells were treated
with lysis buffer (20 mM Tris—pH 8, 150 mM NaCl, 1 mM EGTA,
1 mM MgCl2, 1% deoxycholate, 10 mM glycerophosphate and 10 mM
pyrophosphate) supplemented with a protease inhibitor cocktail. Ten
micrograms of protein samples was then separated by gradient SDS-
PAGE (6–16%) and transferred to a nitrocellulose membrane. The
membrane was then incubated with the following antibodies: anti-
AMPK (Upstate Biotechnology, Lake Placid, NY, USA), rabbit anti-
occludin (ab31721, Abcam), anti-phospho-AMPK, anti-AMPK (Cell
Signaling Technology, Danvers, MA, USA) and anti-actin (MP
Biochemicals, Santa Ana, CA, USA).
Ex vivo imaging
EVs were incubated with 5 μM Cy7 mono NHS ester for 1 h at 37 °C.
Cy7-labeled EVs were isolated using ultracentrifugation and then
injected orally into C57BL/6 mice. After 6 h, the mice were killed, and
tissues were acquired from the liver, fat, muscle, spleen and large
intestine. Cy7 ﬂuorescence was detected by IVIS spectrum, and radiant
efﬁciency was measured using the Living Image 3.1 software (Perkin
Elmer, Waltham, MA, USA).
Clinical studies
Consecutive patients who visited the Department of Endocrinology
and Metabolism at the Asan Diabetes Center were enrolled. This study
was approved by the Asan Medical Center Institutional Review Board
(No. DKUH201401002-HE002). Feces were dissolved in PBS and
centrifuged at 340 g for 10 min. Supernatant fractions were pelleted
twice at 10 000 g for 30 min and ﬁltered through a 0.22-μm syringe
ﬁlter (Sartorius Stedim Biotech, Goettingen, Germany). The ﬁltrates
were then subjected to density-gradient centrifugation in a Beckman
ultracentrifuge (Beckman Coulter) at 100 000 g for 2 h at 4 °C. EVs
were prepared by centrifugation at 200 000 g for 2 h at 4 °C using a
Beckman ultracentrifuge and stored at − 80 °C.
Metagenomic analysis
The 16S rDNA analysis was performed as previously described.23
Brieﬂy, 16S rDNA amplicons were subjected to pyrosequencing using
the 454 GS FLX system (Roche, Basel, Switzerland). DNA sequences
were identiﬁed using the ExTaxon database, after which a metage-
nomic analysis was performed by the ChunLab Corporation (Chun-
Lab Inc., Seoul, South Korea).
Statistical analysis
Clinical EV data were normalized to the fecal data to eliminate the
effects of individual microbiota. The empirical P-values were then
calculated as described in a previous study.32 The heat map based on
these data was drawn using MatLab 2015. The experimental data are
expressed as the mean± s.e.m. Statistical signiﬁcance was calculated
using two-tailed Student’s t-test or analysis of variance with Dunnet’s
multiple comparison correction, where two or more groups were
compared. Differences with Po0.05 were considered statistically
signiﬁcant. Graphs were prepared using the GraphPad Prism V6.01
software (GraphPad Software, La Jolla, CA, USA).
RESULTS
AmEVs are relatively abundant in fecal samples of healthy
humans compared with those of T2D patients
The gut microbial composition has a crucial role in the
maintenance of host health, and a balance of interactions
between gut microbes and host cells is essential for intestinal
homeostasis. It is widely accepted that there is a drastic
alteration in the gut microbial composition between healthy
individuals and patients suffering from metabolic disorders,
including obesity and T2D. EVs are functionally important
mediators of host–pathogen interactions and are thus expected
to differ between healthy and obese/diabetic individuals. Here
we analyzed the fecal EV composition of healthy and diabetic
subjects. Demographics and characteristics of the study subjects
are shown in Supplementary Table S1. We isolated EVs from
human feces (Supplementary Figure S1) and performed
metagenomic analyses for both feces and the corresponding
EVs from healthy controls and T2D patients. In feces from
T2D patients, Firmicutes were dominant compared with those
from healthy controls (Figure 1a). However, the composition
of EVs was different from that of the feces samples, as the 16S
rDNA of Proteobacteria was frequently detected (Figure 1b).
Further analysis of the bacterial population in EVs indicated
that these EVs were composed of diverse species. Because each
individual had different microbiota, the bacterial EV content
was normalized by fecal bacterial content. When comparing the
normalized bacterial EV content between healthy controls and
T2D patients, EVs from A. muciniphila were detected only in
healthy controls (Figure 1c).
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Isolation and characterization of AmEVs
To understand the role played by AmEVs, we next isolated
AmEVs and compared them with E. coli-derived EVs (EcEVs).
Pathogenic strains of E. coli are abundant in individuals
suffering from intestinal inﬂammation and are known to
induce intestinal permeability in vivo and in vitro; hence, they
were used as a control in our study.33–35 Transmission electron
microscopic analysis revealed that both AmEVs and EcEVs
were spherical in shape and had lipid bilayers (Supplementary
Figure S2A). To further characterize the size of the individual
EVs, these vesicles were analyzed using dynamic light scatter-
ing. AmEVs and EcEVs had very similar diameters, with a peak
size range of 40–60 nm (Supplementary Figure S2B). To assess
the protein content of the EVs, simple SDS-PAGE analysis was
performed. As expected, the protein band patterns were
different, reﬂecting a distinct composition of proteins in each
EV (Supplementary Figure S2C). These results suggest that
physical characteristics such as shape and size alone cannot
distinguish AmEVs from EcEVs but that the molecular
compositions of the EVs are different.
Figure 1 Microbial diversity and relative abundances of EVs in human feces. Metagenomic data showing microbial diversity. (a) Microbial
diversity in the feces of type 2 diabetic patients and healthy controls. (b) Microbial diversity in the fecal EVs of type 2 diabetic patients
and healthy controls. (c) Heat map of normalized EV contents. Only species that showed signiﬁcant differences were used to draw this
heat map (Po0.05). The order of species was sorted by the content ratio (type 2 diabetes patients over healthy controls), showing that A.
muciniphila might be a candidate EV-secreting bacterium that suppresses type 2 diabetes.
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Distribution of AmEVs after oral administration
To understand the mechanism of action of EVs in regulating
metabolic functions, we checked the distribution of AmEVs in
peripheral tissues. AmEVs conjugated with Cy7, a near infrared
dye, were injected orally into C57BL/6 mice, and the EV
distribution was examined using near-infrared imaging. After
6 h, in vivo imaging revealed that AmEVs had spread through-
out the mouse body (Figure 2a). Subsequently, the organs were
harvested, and Cy7 signaling in the liver, fat, muscle and other
organs was observed (Figure 2b). Ex vivo images were analyzed
by radiant efﬁciency (Figure 2c). These results suggest that
most of the AmEVs can translocate into the large intestine
within 6 h of feeding.
AmEVs improve gut permeability in HFD-fed mice through
the regulation of tight junctions
To examine the role of AmEVs in vivo, an HFD-fed diabetic
mouse model was employed. C57BL/6 mice were fed either
normal chow diet (NCD) or HFD for 10 weeks, followed by
oral gavaging of AmEVs every other day for 2 weeks
(Supplementary Figure S3A). AmEV feeding signiﬁcantly
reduced HFD-induced body weight gain in these mice
(Figure 3a). To verify whether AmEV administration induced
any changes in in vivo intestinal permeability, the animals were
fasted for 8 h, followed by oral gavaging with 400mg kg− 1
FITC-labeled dextran. The serum FITC concentration was
measured by spectroﬂuorometry. HFD feeding signiﬁcantly
increased gut permeability, as indicated by the increased serum
FITC concentration, which was reduced in AmEV-fed animals
(Figure 3b). HFD feeding drastically reduced the colon length
in mice, and this was also partially ameliorated after AmEV
feeding for 2 weeks (Figures 3c and d). These results show that
HFD induces severe damage in the intestine that affects its
integrity, which can be treated by AmEV feeding. We further
examined colon sections from these animals. Hematoxylin and
eosin staining of the colon sections revealed signiﬁcant damage
to the barrier structure in HFD-fed mice accompanied by the
recruitment of immune cells into the intestinal epithelial layer.
However, in the HFD+AmEV-fed group, damage to the
intestinal epithelial layer was signiﬁcantly lower (Figure 3e,
Supplementary Figure S3B). Because the intestinal barrier
permeability is modiﬁed by altered tight junction protein
expression, we examined the expression of occludin, zonal
occludens and claudin-5, three major tight junction proteins
that are responsible for the maintenance of barrier integrity.36
In concurrence with our intestinal permeability data, HFD
feeding signiﬁcantly reduced the expression of these proteins in
the intestinal epithelial layer, and the expression was increased
in the HFD+AmEV-fed group (Figure 3f, Supplementary
Figure S3C). HFD-induced intestinal permeability is thought
to be a crucial factor for metabolic endotoxemia and diabetes
onset. To verify whether AmEVs had any protective effect on
HFD-induced diabetes, we performed a glucose tolerance test.
AmEV treatment signiﬁcantly improved glucose tolerance in
mice compared with that in mice fed with an HFD alone,
indicating that AmEV treatment was able to improve metabolic
function in HFD-induced diabetic mice (Supplementary
Figure S3D). Overall, these results reveal that AmEV feeding
can protect mice from HFD-induced gut permeability and
improve metabolic functions.
Figure 2 In vivo distribution of Cy7-labeled A. muciniphila-derived EVs in mice. Cy7-labeled AmEVs (50 μg of total protein) were orally
administered to C57BL/6 mice. (a) In vivo ﬂuorescent whole-body images of AmEVs in mice were acquired with an IVIS spectrum. (b) Ex
vivo image of various tissues, including liver, fat, muscle, pancreas, spleen and large intestine, after 6 h of EV feeding. (c) Radiant
efﬁciency was measured using the Living Image 3.1 software. All data are presented as the mean± s.e.m. of 3 experiments, with n=5–7
animals per group for each experiment. *Po0.05.
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Figure 3 A. muciniphila-derived EVs improve gut permeability in high-fat diet (HFD)-fed mice. Mice were fed a normal chow diet (NCD) or
a HFD for 12 weeks, followed by oral administration of AmEVs (10 μg per mouse) every other day for 2 weeks. (a) Body weight changes
were measured at the indicated time points. The graph shows body weight change from the day that EV feeding started. (b) In vivo
intestinal permeability assay in NCD, NCD+AmEV, HFD and HFD+AmEV mice conducted after 4 h of treatment with FITC-dextran. The
serum FITC concentration was measured using blood collected by retro-orbital bleeding, and ﬂuorescence was measured using a
spectroﬂuorometer. Data are shown as the mean± s.e.m. (c) Gross imaging of the colons dissected from NCD-, NCD+AmEV-, HFD- and
HFD+AmEV-fed mice. (d) The colon length of NCD-, NCD+AmEV-, HFD- and HFD+AmEV-fed mice. (e) Hematoxylin and eosin staining of
colon sections from NCD-, NCD+AmEV-, HFD- and HFD+AmEV-fed mice. Red arrows indicate the recruitment of immune cells. Scale bar
is 50 μm. (f) Immunohistochemical images showing occludin expression (occludin—red, nucleus—blue) in NCD-, NCD+AmEV-, HFD- and
HFD+AmEV-fed mice. Scale bar is 50 μm. All data are presented as the mean± s.e.m. of 3 experiments; n=5–7 per group; *Po0.05,
**Po0.01.
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AmEVs improve barrier integrity in Caco-2 cells through
AMPK activation
To verify the mechanism of EVs in tight junction regulation,
we performed in vitro permeability assays using monolayer
cultures of Caco-2 cells. High-calorie and high-fat western-style
diets alter the gut microbial composition and increase the level
of gut microbiome-derived endotoxin or LPS in
circulation.14,37,38 Increased metabolic endotoxemia is thought
to be due to major changes in the gut microbiome, and the
gut-derived LPS could be responsible for the increase in
intestinal permeability.39 To mimic this, Caco-2 transwell
monolayer cultures were treated with LPS alone, EcEVs or
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AmEVs. The decrease in the trans-epithelial electrical resistance
induced by LPS was rescued by the administration of AmEVs
(Figure 4a). The FITC-dextran permeability assay in Caco-2
cells also conﬁrmed that AmEV treatment could improve
intestinal barrier integrity under LPS treatment conditions
(Figure 4b). We observed that only AmEVs and not EcEVs
decreased LPS-induced tight junction permeability (Figures 4a
and b).
Tight junction proteins are major factors that contribute to
intestinal barrier integrity. Analysis of tight junction protein
expression by immunoblotting revealed that the LPS-induced
decrease in occludin expression was ameliorated by AmEV
treatment but remained the same after EcEV treatment
(Figure 4c). To understand the mechanism of the regulation
of tight junction permeability, AmEVs and EcEVs were
administered to Caco-2 cells in a dose- and time-dependent
manner. We found that AmEVs induced phosphorylation of
AMPK, a kinase responsible for tight junction re-assembly and
stability,40–42 in a dose-dependent manner but that EcEVs did
not. AMPK phosphorylation increased steadily following
AmEV treatment in a dose-dependent manner compared with
EcEVs (Figure 4d,Supplementary Figure S4A). AMPK activa-
tion occurred within 1 h of AmEV administration; however,
p-AMPK expression was not changed after EcEV administra-
tion (Figure 4e,Supplementary Figure S4B). AmEV treatment
also improved intestinal barrier integrity in a dose-dependent
manner (Supplementary Figure S4C). Furthermore, to conﬁrm
the role of AMPK in AmEV-induced tight junction regulation,
Caco-2 cells were co-treated with AmEV and AMPK inhibitor
compound C. AmEV treatment could not induce the expres-
sion of occludin in the presence of AMPK inhibitor compound
C (Figure 4f). Similarly, AmEVs’ ability to improve LPS-
induced loss of barrier integrity in vitro was abolished in the
presence of compound C (Supplementary Figures S4D and E).
Collectively, these data suggest that AmEVs are potent AMPK
activators that decrease tight junction permeability in Caco-2
cells. Our results suggest that AmEVs activate the AMPK
pathway, which is responsible for the regulation of tight
junctions.
DISCUSSION
In the present study, we demonstrated the regulatory effect of
AmEVs on intestinal permeability via the regulation of the tight
junction protein occludin through AMPK activation. More-
over, AmEV-treated diabetic mice exhibited improved meta-
bolic proﬁles, including body weight and glucose tolerance. We
also observed that AmEVs were enriched in the feces of healthy
controls compared with those of T2D patients, indicating a
potential role for AmEVs as a therapeutic intervention for
obesity and diabetes.
Maintenance of intestinal barrier integrity is crucial for the
proper physiology and homeostasis in the human body.43–45 A
compromised intestinal barrier integrity can be detrimental46
and lead to the onset of several gastro-intestinal,47–49
metabolic13,50,51 and neurological disorders.52,53 Previous stu-
dies have reported a close association between obesity and the
loss of barrier integrity. Increased intestinal barrier permeability
induces metabolic endotoxemia, which is thought to be a
major factor contributing to metabolic disorders in obesity.54 A
leaky gut allows the passage of gut microbiota-derived LPS into
the blood stream, leading to metabolic endotoxemia, a trigger
for onset of obesity and diabetes. Though it is not clear whether
the loss of barrier integrity is an initial event in the pathogen-
esis of obesity and T2D, a myriad of experimental and clinical
studies reinforces the importance of the maintenance of gut
barrier integrity. Consequently, regulating intestinal barrier
integrity is gaining attention as an intriguing therapeutic
strategy55,56 for metabolic disorders.
The gut microbiota is now widely investigated for its role in
regulating intestinal barrier integrity, host energy balance and
homeostasis by modulating host signaling pathways.57,58 A.
muciniphila, a beneﬁcial gut bacterium, has been previously
identiﬁed to be inversely correlated with body weight in type 2
Figure 4 A. muciniphila-derived EVs reduce LPS-induced intestinal permeability through AMPK phosphorylation. (a) Trans-epithelial
electrical resistance in Caco-2 cells 4 h after treatment with LPS (5 μg ml−1), LPS (5 μg ml−1)+EcEVs (1 μg ml−1) and LPS (5 μg ml−1)
+AmEVs (1 μg ml−1). (b) In vitro permeability assay in Caco-2 cells 4 h after LPS (5 μg ml−1), LPS (5 μg ml−1)+EcEV (1 μg ml−1) and LPS
(5 μg ml−1)+AmEV (1 μg ml−1) treatment. FITC-dextran was added to the upper chamber in the Caco-2 transwell chamber assay, and the
transport of FITC-labeled dextran across the Caco-2 monolayer culture was measured by ﬂuorescence spectroﬂuorometry. (c) Expression of
tight junction proteins in Caco-2 cells after LPS, LPS+EcEV and LPS+AmEV treatments. A graph showing the relative occludin expression
(normalized to actin) is also shown (*Po0.05). (d) AmEV treatment increased occludin expression and phosphorylation of AMPKα2 thr-
172 in a dose-dependent manner. Caco-2 cells were treated with 0.1, 1 and 10 μg ml−1 AmEVs, and the expression of occludin, p-AMPK,
total AMPK and actin was analyzed after 4 h by immunoblotting. A graph showing the relative protein expression normalized to actin is
shown (occludin expression in NT vs the speciﬁed treatment group ##Po0.01, ###Po0.001; p-AMPK expression in NT vs the speciﬁed
treatment group **Po0.01). (e) Time course of AmEV-induced occludin and p-AMPK expression in Caco-2 cells. Caco-2 cells were treated
with 1 μg ml−1 AmEVs, and the expression of occludin, p-AMPK, total AMPK and actin was analyzed after 1, 2, 4 and 8 h by
immunoblotting. The graph shows the relative protein expression after normalization to actin (occludin expression in NT vs the speciﬁed
time point #Po0.05; p-AMPK expression in NT vs the speciﬁed time point *Po0.05, **Po0.01). (f) Western blot showing the effect of
the AMPK inhibitor on AmEV-treated Caco-2 cells. Caco-2 cells were treated with the AMPK-speciﬁc inhibitor compound C for 30 min,
after which 1 μg ml−1 AmEVs was applied. Protein expression of occludin and p-AMPK was observed after 4 h. The graph shows the
relative occludin expression after normalization to actin (occludin expression in NT vs the speciﬁed time point #Po0.05). All data are
presented as the mean± s.e.m. of three experiments performed in triplicate. NS, not signiﬁcant.
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diabetic mice59–61 and has been shown to reverse certain
metabolic parameters, such as insulin resistance.9 An outer
membrane protein of A. muciniphila, Amuc_1100, which
interacts with host Toll-like receptor 2, was recently found to
have an important role in promoting gut barrier integrity
through the upregulation of tight junction proteins and is
thought to be involved in the beneﬁcial properties shown by
this bacterium in patients with obesity and diabetes.62,63
However, the complexities involved in culturing these bacteria
limit their clinical application.
Here we suggest that EVs, complex biological molecules that
mediate interactions between the gut microbiota and the host,
can be potent components for the regulation of intestinal
barrier integrity by the gut microbiome.64–66 EVs are spherical
lipid bilayer structures67 released from bacteria and can enter
the host systemic circulation and induce immunological and
metabolic responses by delivering their components into host
cells and possibly interacting with speciﬁc intracellular
compartments.68,69 We found that EVs derived from A.
muciniphila were responsible for improving intestinal barrier
integrity. We also showed that AmEVs improved body weight
and glucose tolerance in diabetic mice (Figure 3). AmEV
treatment reduced HFD-induced barrier permeability. It is
likely that the resulting improvement in metabolic endotox-
emia could have resulted in the improved metabolic pheno-
types, such as glucose tolerance and body weight. Previous
studies have shown that the feeding of A. muciniphila to HFD-
fed mice can improve metabolic endotoxemia.9,70 However,
until now, little has been known about the direct effects of EVs
on cellular physiology and intestinal barrier regulation. Here
we show that EVs derived from A. muciniphila could be
responsible for the beneﬁcial effects shown by this bacterium.
Therefore, this study provides unique and signiﬁcant insights
into the inﬂuence of EVs on the host and deepens our current
understanding of the role the gut microbiome has in regulating
gut barrier integrity. It should also be noted that AmEVs may
improve the metabolic phenotypes in HFD-fed mice through
other mechanisms. Further in-depth studies are imperative to
decipher the other roles of AmEVs in improving HFD diet-
induced phenotypes.
Furthermore, we demonstrate that AmEVs can activate
AMPK, which is involved in tight junction regulation. The
role of AMPK activation in fortifying epithelial tight junctions
has been widely studied.42 AMPK is essential for the assembly
of tight junction proteins at cell–cell junctions, and initiation of
tight junction assembly is compromised in cells lacking active
AMPK.41,42 EVs derived from A. muciniphila promote tight
junction expression by activating AMPK. This was proven by
the abolishment of the effects of AmEVs after AMPK inhibitor
treatment (Figure 4).
However, it is yet to be determined what component of
AmEVs activates AMPK. Here we simply visualized the protein
banding patterns of AmEVs and EcEVs using SDS-PAGE. Our
analysis revealed different protein contents in the two different
EVs, and this difference may contribute to the varying effects of
each EV, as proteins are typically the functional component.
However, proteins are not the only molecules that can
inﬂuence the physiological condition of the cells. Therefore,
ﬁnding the effective component in the EVs is a challenging
task, as these vesicles are composed of several molecules,
including proteins, lipids, nucleic acids and other factors.71,72
Proteomic or lipidomic experiments would help to identify the
speciﬁc molecule or molecules in AmEVs that contribute to the
regulation of intestinal barrier integrity.
Here we focused on the role of EVs in promoting intestinal
barrier integrity. Convincing evidence supporting a role for
EVs as arbitrators of microbiome–host signaling is only starting
to emerge. In this study, for the ﬁrst time, we identiﬁed a
potential role for EVs from A. muciniphila in improving gut
barrier integrity under pathophysiological conditions induced
by high-calorie eating habits. We observed that AmEVs from
gavage penetrate the large intestine and spread to peripheral
tissues. However, our results do not verify whether EVs
remained intact after traveling throughout the body. Moreover,
there are no data on the ratio of EVs in the gut to EVs in
peripheral tissues. It is important to measure these circulating
vesicles in order to determine the efﬁciency of EV inﬂuence on
host cells. It would also be interesting to investigate the role of
EVs in peripheral tissues such as muscle, adipose tissue and
liver and how EV–host interactions at the tissue level con-
tribute to physiology and homeostasis. Thus further investiga-
tions to identify the pathways of EVs will provide a more
thorough understanding of the mechanisms underlying the
complex role of EVs in physiological and pathophysiological
conditions.
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